ABSTRACT
Introduction
Natural killer (NK) cells belong to innate lymphoid immune cells that contribute to anti-tumor responses without prior sensitization. According to the currently applied innate lymphoid cell (ILC) nomenclature, NK cells are a prototypical member of the group 1 ILCs in so far as they produce IFN-γ and developmentally require the common cytokine receptor gamma chain (γc), the transcriptional repressor inhibitor of DNA binding 2 (ID2) and T-bet 1 . During maturation, NK cells sequentially acquire lineage-specific markers such as CD94, NKp46, CD56 and CD16. Based on the surface density of CD56, the primarily cytokine-producing to kill target cells which have lost MHC class I 3 . In a balanced state, healthy tissue that expresses the "self" ligands to inhibitory NK cell receptors, i.e. certain MHC class I molecules, will be spared from being killed. In contrast, the recognition of missing or downregulated "self"-MHC class I molecules on tumor cells by licensed NK cells shifts the NK cell receptor balance towards activation. Altogether, the modulation of NK cell activity is controlled by an array of germline-encoded activating and inhibitory receptors as well as modulating coreceptors which are summarized in Figure 1 and reviewed by 4 .
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The biological basis for NK cell alloreactivity
Since attempts to exploit autologous NK cells either by in vivo stimulation with IL-2 5 or the infusion of ex vivo stimulated autologous NK cells 6 showed limited clinical efficacy, the focus of research was directed towards the use of NK cells from healthy related or unrelated donors in the context of allogeneic cell therapy.
In this context, donor NK cells that express an inhibitory KIR for which the respective ligand is absent on the recipient's leukemic cells and that concomitantly lack the expression of CD94/NKG2A -as HLA-E molecules are present on all cells and will as a result inhibit NK cell functionality -are defined as being alloreactive 7 . KIRs are genetically determined and highly polymorphic receptors that recognize allotypic variants of MHC class I alleles (KIR Ligands, KIRL) 8 . Molecular cloning has revealed that distinct groups of family members comprise two or three extracellular immunoglobulin-like domains and hence are designated KIR2D and KIR3D, respectively. KIRs with inhibitory activity are long-tailed in their intracytoplasmic region as indicated by the letter "L" (i.e. 2DL1) whereas their activating KIR counterparts are short-tailed as indicated by the letter "S" (i.e. 2DS1 of these conceptual differences the term "KIR-KIRL mismatch" is used inconsistently and this inconsistency may in part explain why some of the models are more or less able to predict outcome. In Figure 2, .
In conclusion, quite a number of association studies suggest that a donor with an inhibitory KIR-KIRL mismatch towards the recipient, who possesses aKIRs next to iKIRs and who ideally expresses not one but multiple aKIRs will be a potentially "optimal" donor that may promote clinically relevant NK cell alloreactivity ( Figure   3 ). However, given the complexity of the transplant procedure and the strong linkage Interestingly, murine and preclinical in vitro studies suggest that NK cells are actively suppressed by regulatory T cells 54 and it has been assumed that this suppression also 
Allogeneic stem cell transplantation and NK cell reconstitution
To predict whether a theoretically existing KIR-KIRL mismatch will actually translate into NK cell alloreactivity and thus increase GvL effects, it might be useful to integrate the complexity and the kinetics of NK cell reconstitution into the picture. Donor NK cells which reconstitute, develop and mature in a HLA-disparate recipient will be shaped in the predominantly donortype-like hematopoietic niche 56 and are thus donor-tolerant and recipient-alloreactive at least in the first months after transplantation 26;33;40;57 . Keeping the complex process of "licencing"
or "education" of NK cells in mind, it is obvious that the density of donor-derived HLA class I molecules is crucial to the question whether emerging NK cells will be alloreactive or not. In line with this it has been postulated that the infusion of "megadoses" of stem cells will enable better acquisition of NK cell maturity than the infusion of usually applied doses 9 . However, many aspects in the processes that are involved in the maturation and education of NK cell populations after HSCT are at present unclear. It has been shown that NK cells are among the first lymphocytes to reconstitute to desirable cell numbers (of more than 0.1x 10 9 /L CD56 + cells) within the first month after transplantation both in adults 58;59 and in children 33;40;60 and that the reconstitution kinetics may inversely correlate to relapse probability 59;61 .
However, the phenotype and cytolytic activity of reconstituting NK cells significantly depends on the pre-conditioning regime, the source of the graft and the mode of transplantation. NK cell reconstitution was shown to be impaired in patients that had been exposed to reduced- homozygous. Here, the activating signal of KIR2DS1 will overcome the inhibition of KIR2DL2/3 whereas in HLA-C2 donors KIR2DS1 will dampen NK cell functionality to prevent auto-reactivity 70 . A summary of the KIR-KIRL combinations that effectively contribute to NK cell alloreactivity is shown in Table 1 .
In our observation, a substantial number of potentially alloreactive donor-derived NK cells expressing only a single iKIR were detectable after HLA-mismatched HSCT. Interestingly, KIR2DL2/3 was predominantly expressed irrespective of the patients' HLA type. This may explain why patients homozygous for the C1 group (C1/C1) and therefore expressing more . Although the precise mechanisms of adaptive NK cell conversion remain elusive, a simplified view could be that in the context of viral infection a pro-inflammatory stimulus disrupts the tumor-induced immunosuppression and promotes NK cell alloreactivity towards leukemia. but not KIR2DL2 has allowed a more precise analysis of potentially alloreactive NK cell subsets that a donor might express towards a given leukemia 84 . regulated by iKIRs and NKG2A but promoted by KIR2DS1 89 . As non-hematopoetic host tissues such as the skin, which is commonly affected from T cell-mediated GvHD, lack the expression of activating NK cell receptor ligands, the skin appears to be comparatively resistant to NK cell-mediated attack. It is currently assumed that in some instances NK cells might contribute to pathology once GvHD is established 90 . In this regard, the mode of transplantation (i.e. extent of T cell depletion) and the mode of NK cell stimulation (i.e.
Alloreactive NK cells promote GvL effects in the absence of GvHD
adoptive transfer with IL-15/4-1BBL activated and expanded NK cells) may affect GvHD occurrence 91 .
Overcoming KIR-KIRL-mediated inhibition and increasing the anti-leukemic effects of NK cells
One approach to counteract NK cell suppression induced by the KIR-KIRL interactions is the use of IPH2101, the first-in-class, non-depleting IgG 4 monoclonal antibody directed against KIR2DL1 and KIR2DL2/3. Indeed, IPH2101 therapy has been effectively able to restore NK cell alloreactivity in adult AML patients 92 , and preliminary in vitro experiments also suggest effectiveness towards pediatric BCP-ALL specimens 69 . An additional approach to activate alloreactive but also non-alloreactive NK cells is the use of monoclonal antibodies directed against antigens expressed on leukemic blasts. It has been shown that the activation of NK cells via the Fc-receptor CD16, which induces antibody-dependent cellular cytotoxicity (ADCC), provides a strong activatory signal and overrides the inhibitory effects of the KIR-KIRL interaction 93 Since the CD19 antigen is widely expressed on BCP-ALL, an Fcoptimized anti-CD19 antibody was constructed and used post-transplant in selected high-risk patients with pediatric BCP-ALL 94 . In Figure 5 , the various approaches to overcome the KIR-KIRL-mediated inhibition and to increase the cytotoxicity towards leukemic cells in the autologous or allogeneic setting are shown. 
PERSPECTIVE
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